Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

CRISPRi: a way to integrate iPSC-derived neuronal models.

Franks SNJ. et al, (2024), Biochem Soc Trans, 52, 539 - 551

Correction: Multi-modal proteomic characterization of lysosomal function and proteostasis in progranulin-deficient neurons.

Hasan S. et al, (2023), Mol Neurodegener, 18

Multi-modal proteomic characterization of lysosomal function and proteostasis in progranulin-deficient neurons.

Hasan S. et al, (2023), Mol Neurodegener, 18

Mitochondrial dysfunction and mitophagy defects in LRRK2-R1441C Parkinson's disease models.

Williamson MG. et al, (2023), Hum Mol Genet, 32, 2808 - 2821

Post-translational proteomics platform identifies neurite outgrowth impairments in Parkinson's disease GBA-N370S dopamine neurons.

Bogetofte H. et al, (2023), Cell Rep, 42

Multi-modal Proteomic Characterization of Lysosomal Function and Proteostasis in Progranulin-Deficient Neurons.

Hasan S. et al, (2023), bioRxiv

Multiparameter phenotypic screening for endogenous TFEB and TFE3 translocation identifies novel chemical series modulating lysosome function.

Carling PJ. et al, (2023), Autophagy, 19, 692 - 705

Identification of a possible proteomic biomarker in Parkinson's disease: discovery and replication in blood, brain and cerebrospinal fluid.

Winchester L. et al, (2023), Brain Commun, 5

Multi-modal Proteomic Characterization of Lysosomal Function and Proteostasis in Progranulin-Deficient Neurons

Hasan S. et al, (2023), JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 82, 541 - 541

Identification of a novel proteomic Biomarker in Parkinson’s Disease: Discovery and Replication in Blood, brain and CSF

Winchester L. et al, (2021)

Erratum: Ryan et al., "REST Protects Dopaminergic Neurons from Mitochondrial and α-Synuclein Oligomer Pathology in an Alpha Synuclein Overexpressing BAC-Transgenic Mouse Model".

(2021), J Neurosci, 41

A novel post-translational proteomics platform identifies neurite outgrowth impairments in Parkinson’s diseaseGBA-N370Sdopamine neurons

Bogetofte H. et al, (2021)

Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism.

Okarmus J. et al, (2021), Stem Cell Reports, 16, 1510 - 1526

REST Protects Dopaminergic Neurons from Mitochondrial and α-Synuclein Oligomer Pathology in an Alpha Synuclein Overexpressing BAC-Transgenic Mouse Model.

Ryan BJ. et al, (2021), J Neurosci, 41, 3731 - 3746

Mitochondrial Dysfunction and Mitophagy in Parkinson's Disease: From Mechanism to Therapy.

Malpartida AB. et al, (2021), Trends Biochem Sci, 46, 329 - 343

Striatal Dopamine Transporter Function Is Facilitated by Converging Biology of α-Synuclein and Cholesterol.

Threlfell S. et al, (2021), Front Cell Neurosci, 15

Lysosomal perturbations in human dopaminergic neurons derived from induced pluripotent stem cells with PARK2 mutation.

Okarmus J. et al, (2020), Sci Rep, 10

Enhancing mitophagy as a therapeutic approach for neurodegenerative diseases.

Aman Y. et al, (2020), 155, 169 - 202

Perturbations in RhoA signalling cause altered migration and impaired neuritogenesis in human iPSC-derived neural cells with PARK2 mutation.

Bogetofte H. et al, (2019), Neurobiol Dis, 132

Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons.

Zambon F. et al, (2019), Hum Mol Genet, 28, 2001 - 2013

Load More

Include forthcoming?